ArticleJournal of clinical medicine2021

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.

Edoardo Lenci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.